Primary Aldosteronis diagnosed by increased Renin ratio (ARR) and serum aldosterone levels ≥15 ng / dl, and confirmed by saline injection test or captopril inhibition test.
Idiopathic aldosteronism, bilateral adrenal hyperplasia, and unilateral adrenal hyperplasia with no superior secretion confirmed with adrenal CT and adrenal venous blood (AVS).
The patients was diagnosed with aldosteronoma or unilateral adrenal hyperplasia but refused to surgical excision.
Signed informed consent and agreed to participate in this study.
You may not be if
Aldosterone cancer.
Hyperkalemia.
Renal failure or the following history of nephropathy: serum creatinine 1.5 times higher than the upper limit; dialysis history; or nephrotic syndrome.
Secondary hypertension except the primary aldosteronism.
Adrenergic insufficiency.
Heart failure with NYHA grade Ⅱ-Ⅳ grade or unstable angina, severe cardiovascular and cerebrovascular stenosis, myocardial infarction, intracranial aneurysm, stroke and other acute cardiovascular events.
Acute infections, tumors and severe arrhythmias, psychiatric disorders, drugs or alcohol addicts.
Liver dysfunction or the following history of liver disease: AST or ALT 2 times higher than the upper limit, liver cirrhosis, history of hepatic encephalopathy, esophageal variceal history or portal shunt history.
Coagulation dysfunction.
Pregnant women or lactating women.
Participated in other clinical trials or admitted with other research drugs within 3 months prior to the trial.
Any surgical or medical condition which can significantly alter the absorption, distribution, metabolism, or excretion of any study drug.
Allergy or any contraindications for the study drugs, contrast agents and alcohol.
Refused to sign informed consent
Clareo Health | Effects of Adrenal Artery Ablation and Spironolactone in Patients With Primary Aldosteronism
